Abstract
Anticoagulation for atrial fibrillation has been dependant on warfarin for the past 30 years. However, the recent FDA approvals of dabigatran and rivaroxaban and the expected approval for apixaban have provided several new alternatives for our patients. Many factors must be considered when selecting the most appropriate agent for preventing stroke in nonvalvular atrial fibrillation. The following trials have provided the foundation for decision making when considering alternatives to warfarin therapy.
Keywords:
anticoagulation; apixaban; dabigatran; nonvalvular atrial fibrillation; rivaroxaban.
MeSH terms
-
Anticoagulants / therapeutic use*
-
Antithrombins / therapeutic use
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / drug therapy*
-
Benzimidazoles / therapeutic use
-
Dabigatran
-
Humans
-
Morpholines / therapeutic use
-
Pyrazoles / therapeutic use
-
Pyridones / therapeutic use
-
Rivaroxaban
-
Stroke / etiology
-
Stroke / prevention & control*
-
Thiophenes / therapeutic use
-
Warfarin / therapeutic use
-
beta-Alanine / analogs & derivatives
-
beta-Alanine / therapeutic use
Substances
-
Anticoagulants
-
Antithrombins
-
Benzimidazoles
-
Morpholines
-
Pyrazoles
-
Pyridones
-
Thiophenes
-
beta-Alanine
-
apixaban
-
Warfarin
-
Rivaroxaban
-
Dabigatran